Merck’s tie-up with Idenix creates a new competitor for Gilead

The company’s shares fell about 4% Monday, after Merck & Co. announced it was buying Idenix Pharmaceuticals Inc. in a $3.85 billion deal aimed at bolstering its pipeline of hepatitis C treatments. Idenix IDIX is a biopharmaceutical company that specializes in treatments for human viral illnesses. Idenix currently has three…

Read More

9th Pan Arab Congress of Pan Arab Association of Gastroenterology Endorsed By: WGO & WEO That will be held in Tunis through the period, October 9-11, 2014

  9th Pan Arab Congress of Pan Arab Association of Gastroenterology Endorsed By: WGO & WEO That will be held in Tunis through the period, October 9-11, 2014  Main Topics are: Viral Hepatitis, Inflammatory Bowel Disease, Barett Esophagus, Hepatocellular Carcinoma, Liver Transplantation, GIST, Portal Thrombosis,GERD, H Pylori Infection, NASH, Drug…

Read More

Toxic hepatitis induced by a herbal medicine: Tinospora crispa

Authors: Langrand J, Regnault H, Cachet X, Bouzidi C, Villa AF, Serfaty L, et al. Source: Phytomedicine. 2014;21(8-9):1120-3. Abstract: Herbal remedies are becoming increasingly popular in many countries. Tinospora species (Menispermaceae) is commonly used as a herbal medicine in South Asia, but very few toxic effects have been described. We…

Read More

Hepatitis B vaccine birthdose practices in a country where hepatitis B is endemic – Laos, December 2011-February 2012

Source: MMWR Morb Mortal Wkly Rep. 2013;62(29):587-90. Abstract: Chronic hepatitis B virus (HBV) infection causes approximately 325,000 deaths from cirrhosis and liver cancer each year in the Western Pacific Region of the World Health Organization (WHO). With an estimated infection prevalence of >8%, HBV is considered highly endemic in Laos…

Read More

Gilead Announces Phase 3 Data Showing That the Fixed-Dose Combination of Ledipasvir/Sofosbuvir Achieved 100 Percent Sustained Virologic Response (SVR12) Among Patients with Chronic Hepatitis C in Japan

Interferon- and Ribavirin-Free Therapy Effective against Genotype 1 HCV, Japan’s Most Prevalent Strain of the Disease —   FOSTER CITY, Calif.–(BUSINESS WIRE)–Jun. 15, 2014– Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from a Phase 3 clinical trial (GS-US-337-0113) in Japan evaluating the investigational once-daily fixed-dose combination of the…

Read More

Hepatitis C viremia patterns in incident hepatitis C infection and one year later in 150 prospectively tested persons who inject drugs

Authors: Alanko Blome M, Bjorkman P, Molnegren V, Hoglund P, Widell A. Source: PLoS One. 2014;9(5):e97022. OBJECTIVES: To assess HCV viremia levels just before, during and one year after anti-HCV seroconversion in people who inject drugs (PWID). METHODS: PWID enrolling into a needle exchange program in Malmo, Sweden, 1997-2005 constituted…

Read More

The IFN-lambda Genetic Polymorphism Association with the Viral Clearance Induced by Hepatitis C Virus Treatment in Pakistani Patients.

Authors: Tipu I, Marriage F, Farooqi ZU, Platt H, Athar MA, Day PJ, et al. Source: Hepat Mon. 2014;14(3):e15076. Abstract: BACKGROUND: Polymorphisms in the interferon lambda (INF lambda) genes on chromosome 19 have been associated with clearance of hepatitis C virus (HCV) induced by interferon and ribavirin therapy however there…

Read More